IRIDEX Q2 Loss Widens on Retina Weakness Despite Cyclo G6 Growth; Stock Slides 15%

What happened

IRIDEX reported Q2 FY2026 results showing a widening year-over-year loss and declining revenue, driven by Middle East disruptions and reduced sell-through in China impacting its retina product lines. The decline was partially offset by continued growth in the Cyclo G6 product family, which remains the core of the company's utilization-led consumables strategy. The master report had set a checkpoint that probe units must show year-over-year growth by Q2 FY2026 results to validate the thesis, and while Cyclo G6 grew, the overall revenue decline suggests the company is not meeting the broader financial expectations. The stock's 15% drop reflects investor disappointment that the company's overall performance is still negative despite the consumables traction. The weakening in retina sales, which is a lower-margin and less strategic segment, raises concerns about the company's ability to achieve overall profitability and free cash flow, which were central to the earlier potential buy rating.

Implication

The prior thesis hinged on probe growth and cost discipline leading to improved cash flow and reduced financing risk, but the Q2 results show that overall revenue is declining due to non-core segments, which pressures the bottom line. The continued growth in Cyclo G6 is a positive, but it is insufficient to offset the declines elsewhere, and the company's cash burn may re-emerge. The stock's drop below the attractive entry level of $1.30 might tempt some, but the loss of confidence in management's ability to deliver broad-based growth warrants caution. The next quarter will be critical to see if the retina weakness is temporary or structural, and whether the Cyclo G6 growth can accelerate enough to return to revenue growth. Until the company demonstrates it can grow overall revenue and contain losses, the equity remains high risk and is better suited for aggressive investors with a high tolerance for volatility.

Thesis delta

Initially, the report had a positive stance based on probe growth and expected cash flow improvement, but the new Q2 results contradict that by showing a loss and revenue decline. The thesis must be revised to acknowledge that non-core segment weakness may offset the consumables growth, and the path to sustainable profitability is now less certain. The stock's 15% drop validates that the market is pricing in a higher probability of the bear case.